Pfizer (PFE) Tops Q3 EPS by 2c, Lifts FY EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
PFIZER REPORTS THIRD-QUARTER 2017 RESULTS
October 31, 2017 6:45 AM EDTThird-Quarter 2017 Revenues of $13.2 Billion, Reflecting 1% Operational Growth; Unfavorably Impacted by $281 Million, or 2%, Due to the February 2017 Divestiture of Hospira Infusion Systems (HIS) Third-Quarter 2017 Reported Diluted EPS(1) of $0.47, Adjusted Diluted EPS(2) of $0.67 Narrowed Certain 2017 Financial Guidance Ranges; Raised Midpoint of Adjusted Diluted EPS(2) Guidance Range by $0.03 to a Range of $2.58 to $2.62
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) reported financial results for third-quarter 2017 and narrowed certain 2017 financial guidance ranges.
Results for the third quarter and first nine months of 2017 and 2016(3) are summarized below.
 OVERALL RESULTS              ($ in millions, exceptper share amounts)
Third-Quarter Nine Months 2017 Â ... More